GFM
RNAC icon

GF Fund Management’s Cartesian Therapeutics RNAC Stock Holding History

GF Fund Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-549
Closed -$5.61K – 689
2025
Q3 		$5.61K Sell
549
-101
-16% -$1.14K ﹤0.01% 603
2025
Q2 		$6.75K Hold
650
– – ﹤0.01% 607
2025
Q1 		$8.57K Buy
650
+116
+22% +$2.07K ﹤0.01% 583
2024
Q4 		$9.56K Buy
+534
New +$10.8K ﹤0.01% 551

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GF Fund Management's RNAC Position: Q4 2025 in Review

GF Fund Management sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 549 shares — an estimated $5.61K sold.

GF Fund Management first reported a position in RNAC in Q4 2024 and held it in 4 quarters. The position peaked at $9.56K in Q4 2024. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • GF Fund Management reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GF Fund Management sold 549 Cartesian Therapeutics shares in Q4 2025, an estimated $5.61K.
  • GF Fund Management first reported a position in Cartesian Therapeutics in Q4 2024 and held it in 4 quarters.
  • GF Fund Management's Cartesian Therapeutics position peaked at $9.56K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.